Correction: *Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study*

Tanaka Y, Hirata S, Kubo S, *et al.* Discontinuation of adalimumab after achieving remission in patients with established rheumatoid arthritis: 1-year outcome of the HONOR study. *Ann Rheum Dis* 2015;74:389–95. In table 3 (B) values of 95% CI were not correct. The corrected table 3 (B) is given below.

Table 3 (B) Multivariate logistic regression analysis

Items	Odds	95%CI	Chi-square	p Value
Age (years)	0.963	0.906 to 1.024	1.441	0.2300
ADA admin periods (weeks)	0.985	0.959 to 1.011	1.254	0.2629
DAS28-ESR	0.143	0.029 to 0.711	5.653	0.0174*
RF (U/mL)	1.012	0.996 to 1.028	2.127	0.1448

Univariate logistic regression analysis was performed using items with $p < 0.1$ in table 2 to investigate factors related to sustained remission for 1 year after ADA discontinuation. Then, multivariate analyses were conducted using the variables with $p < 0.2$ in the univariate analysis. Using the DAS28-ESR values which were significant in logistic analysis, ROC analysis was conducted with the response (dependent) variable of if DAS28-ESR < 2.6 (1) or ≥ 2.6 (0) 1 year after discontinuation of ADA and the explanatory variable of DAS28-ESR at the timing of ADA discontinuation.

* $p < 0.01$: Wald test.

ADA, adalimumab; DAS28, disease activity score 28; RF, rheumatoid factor.

Ann Rheum Dis 2016;75:e46. doi:10.1136/annrheumdis-2013-204016corr1

CrossMark